Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Treasury Shares: 2023-2024

  • Stoke Therapeutics' Treasury Shares fell 19.18% to $1.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.2 million, marking a year-over-year decrease of 19.18%. This contributed to the annual value of $1.2 million for FY2024, which is 19.18% down from last year.
  • As of Q4 2024, Stoke Therapeutics' Treasury Shares stood at $1.2 million, which was down 19.18% from $1.5 million recorded in Q4 2023.
  • In the past 5 years, Stoke Therapeutics' Treasury Shares registered a high of $1.5 million during Q4 2023, and its lowest value of $1.2 million during Q4 2024.
  • Moreover, its 2-year median value for Treasury Shares was $1.4 million (2023), whereas its average is $1.4 million.
  • Data for Stoke Therapeutics' Treasury Shares shows a maximum YoY fell of 19.18% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Stoke Therapeutics' Treasury Shares stood at $1.5 million in 2023, then dropped by 19.18% to $1.2 million in 2024.